Breast International Group

Asia Breast Cancer Screening Market Size and Forecast Report 2023-2028: Industry Trends, Growth, Share, Outlook, Opportunities, and Competitive Landscape - ResearchAndMarkets.com

Retrieved on: 
Friday, January 19, 2024
Oncology, Health, Consumer, Women, Health Technology, Other Health, Ageing, Obesity, Woman, Mammography, Patient, Breast, Infection, Research, MRI, TSCO, KCSG, Breast cancer, Government, Life expectancy, Investment, BIG, Urbanization, CMEA, Tobacco, Non-governmental organization, Breast disease, Diagnosis, Breast International Group, Medical imaging

The "Asia Breast Cancer Screening Market, Size, Forecast 2023-2028, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Asia Breast Cancer Screening Market, Size, Forecast 2023-2028, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • With its rapid population growth trajectory, India is poised to make significant strides in the Asia Breast Cancer Mammography Screening industry
    By Mammography Screening, Asia Breast Cancer Screening Market is segmented into China, India, Japan, Korea, Singapore, Thailand and Malaysia.
  • By MRI Screening, Asia Breast Cancer Screening Market is divided into China, Japan, India, Korea, Singapore, Thailand and Malaysia.
  • With its accelerating growth rate, China is poised to dominate the Asia Breast Cancer Ultrasound Screening industry
    By Ultrasound Screening, Asia Breast Cancer Screening Market is classified into China, Japan, Korea, Singapore, India, Thailand and Malaysia.

Breast International Group (BIG) Highlights Innovations and Challenges in Breast Cancer Research, Exclusive Interview by Xtalks

Retrieved on: 
Tuesday, December 5, 2023
Breast International Group, Disease, BIG, Breast cancer, Research, Patient, Interview, Birth control, Pharmaceutical industry

TORONTO, Dec. 5, 2023 /PRNewswire-PRWeb/ -- In an exclusive interview, Xtalks delves into the current state of breast cancer research, highlighting the role of clinical trials and the integration of patient perspectives in clinical research. Featuring Dr. David Cameron, Chair of the Breast International Group (BIG), the discussion revolves around the importance of collaboration and patient involvement in breast cancer clinical research.

Key Points: 
  • TORONTO, Dec. 5, 2023 /PRNewswire-PRWeb/ -- In an exclusive interview, Xtalks delves into the current state of breast cancer research, highlighting the role of clinical trials and the integration of patient perspectives in clinical research.
  • Featuring Dr. David Cameron, Chair of the Breast International Group (BIG), the discussion revolves around the importance of collaboration and patient involvement in breast cancer clinical research.
  • Dr. Cameron emphasized the importance of international collaboration in advancing breast cancer research.
  • BIG, as the leading global network of academic breast clinical trialists, is spearheading international efforts to innovate treatment options and
    understand the complexities of breast cancer.

Wolters Kluwer collaborates with German publishing company C.H.Beck

Retrieved on: 
Monday, November 13, 2023
Research, University of Oxford, IP, Breast International Group, AAA, American Arbitration Association, International Marxist Group, Wolters Kluwer, Oxford University Press, OUP, Practice of law

NEW YORK, Nov. 13, 2023 /PRNewswire/ -- Wolters Kluwer Legal & Regulatory U.S. today announced a new collaboration with the German publishing company C.H.Beck. Kluwer Arbitration and Kluwer IP Law subscribers can now gain integrated access to key titles from C.H.Beck, and have easy access to the most complete and valuable analysis in arbitration and IP law.

Key Points: 
  • NEW YORK, Nov. 13, 2023 /PRNewswire/ -- Wolters Kluwer Legal & Regulatory U.S. today announced a new collaboration with the German publishing company C.H.Beck.
  • Kluwer Arbitration and Kluwer IP Law subscribers can now gain integrated access to key titles from C.H.Beck, and have easy access to the most complete and valuable analysis in arbitration and IP law.
  • Kluwer Arbitration and Kluwer IP Law customers will now have access to nine well-respected titles offering immediate and practical value.
  • Wolters Kluwer also recently extended its collaborations with both Oxford University Press (OUP) and the American Arbitration Association (AAA), licensing a selection of key titles published by OUP and AAA for Kluwer Arbitration, Kluwer Competition Law , and Kluwer IP Law.

European Organisation for Research and Treatment of Cancer & the Menarini Group Launch New Clinical Trial in Early-Stage Breast Cancer

Retrieved on: 
Thursday, October 19, 2023
European Organisation for Research and Treatment of Cancer, Patient, Research, Arm, Metastasis, Plasma, Clinical trial, European Commission, III, SERD, Treatment, SUCCESS, EORTC, Menarini, HIV disease progression rates, German, DNA, Civil service commission, MBC, MRD, Breast cancer, Breast International Group, Woman, Neoplasm, Death, Treat, BIG, Pharmaceutical industry, Medical imaging, Cancer

A molecular residual disease (MRD) test for the detection of circulating tumour DNA (ctDNA) will also be used.

Key Points: 
  • A molecular residual disease (MRD) test for the detection of circulating tumour DNA (ctDNA) will also be used.
  • The study was submitted under the new Clinical Trial Regulation, and it is expected to start the activation process in the fourth quarter of 2023.
  • "We are excited to offer to our high-risk, ctDNA positive, ER+/HER2- early-stage breast cancer patients the possibility to participate in the Treat ctDNA trial.
  • This intergroup trial, managed by the EORTC Breast Cancer Group, will be jointly conducted with several national and international cancer clinical research groups, including the German SUCCESS group under the umbrella of BIG (Breast International Group).

Wolters Kluwer announces collaboration with CLOCKSS

Retrieved on: 
Thursday, August 10, 2023
CLOCKSS, International Marxist Group, Breast International Group, Metadata, Wolters Kluwer, Collection, Library, Stanford University, Cryptocurrency, Book

NEW YORK, Aug. 10, 2023 /PRNewswire/ -- Wolters Kluwer Legal & Regulatory U.S. today announced its collaboration with global digital preservation services provider CLOCKSS. Thanks to this relationship, customers will now have unlimited digital access to Wolters Kluwer's extensive collection of legal content for the academic market.

Key Points: 
  • NEW YORK, Aug. 10, 2023 /PRNewswire/ -- Wolters Kluwer Legal & Regulatory U.S. today announced its collaboration with global digital preservation services provider CLOCKSS .
  • "Wolters Kluwer Legal & Regulatory U.S. is pleased to collaborate with CLOCKSS to ensure the long-term availability of our global list of Kluwer Law International branded publications," said David Bartolone, General Manager for the International Group at Wolters Kluwer Legal & Regulatory U.S. "By archiving with CLOCKSS, we are ensuring the digital preservation of valuable international legal insights from our renowned author community."
  • All of this material from Wolters Kluwer will be available on CLOCKSS by the end of this year.
  • "The CLOCKSS archive is delighted to collaborate with Wolters Kluwer to preserve international legal information," said Alicia Wise, Executive Director of CLOCKSS.

Wolters Kluwer Expands Its International Arbitration Content through Gary Born Partnership

Retrieved on: 
Tuesday, September 6, 2022
Euronext, Partnership, Technology, ADR Institute of Alberta, Center on International Commercial Arbitration, WKL, International Group, Solution, Wolters Kluwer, Ethics, AEX, Accounting, Lawyer, Breast International Group, Euronext Amsterdam, Compliance, ADR, Risk, American, Content, Practice of law

NEW YORK, Sept. 6, 2022 /PRNewswire/ -- Wolters Kluwer Legal & Regulatory U.S. today announced an expansion of Kluwer Arbitration's partnership with Gary Born's "International Commercial Arbitration." The expanded partnership provides readers with periodically updated authoritative commentary on all aspects of the international commercial arbitration process. The updated content will be available exclusively to Kluwer Arbitration subscribers.

Key Points: 
  • NEW YORK, Sept. 6, 2022 /PRNewswire/ -- Wolters Kluwer Legal & Regulatory U.S. today announced an expansion of Kluwer Arbitration's partnership with Gary Born's "International Commercial Arbitration."
  • The expanded partnership provides readers with periodically updated authoritative commentary on all aspects of the international commercial arbitration process.
  • Gary Born's "International Commercial Arbitration" is a three-volume, authoritative 4,250-page treatise, which includes comprehensive commentary and analysis on all aspects of the international commercial arbitration process with references to more than 20,000 cases.
  • It is the preeminent work on international arbitration and is relied upon by leading national courts, as well as arbitral tribunals, around the world.

Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis® Diagnostic System as a Companion Diagnostic for Lynparza® in Early-Stage Breast Cancer

Retrieved on: 
Thursday, August 25, 2022
MSD, AstraZeneca, BRCA2, Olaparib, Precision medicine, U.S. Securities and Exchange Commission, Myriad Genetics, GLOBE, Classification, Olympia, Tf–idf, Risk, Patient, BRCA1, Genetics, Death, Genetic testing, SALT, DNA, Cancer, Biomarker, Partnership, MHLW, NASDAQ, Breast International Group, Association for Molecular Pathology v. Myriad Genetics, Inc., New Frontiers Science Park, Ministry of Health, Labour and Welfare, Prequel, Myriad, Private Securities Litigation Reform Act, BRCA, Breast cancer, HIV disease progression rates, MYGN, Nominal interest rate, Sumathi Best Television Current Reporting Award, Fast Company, HER2, Medical imaging, Pharmaceutical industry, Health

This most recent coverage expansion confirms the benefits of using biomarkers to help guide care for patients with breast cancer, said Nicole Lambert, chief operating officer, Myriad Genetics.

Key Points: 
  • This most recent coverage expansion confirms the benefits of using biomarkers to help guide care for patients with breast cancer, said Nicole Lambert, chief operating officer, Myriad Genetics.
  • BRACAnalysis Diagnostic System is designed to detect and interpret germline BRCA1 and BRCA2 variants.
  • The test identifies deleterious or suspected deleterious germline BRCA variants in patients with HER2-negative high-risk early breast cancer.
  • BRACAnalysis is a diagnostic system that classifies a patients clinically significant variants (DNA sequence variations) in the germline BRCA1 and BRCA2 genes.

Press Release: Sanofi provides update on amcenestrant clinical development program

Retrieved on: 
Wednesday, August 17, 2022
FDA, Intellectual property, Letrozole, Forward-looking statement, Private Securities Litigation Reform Act, SEC, Toxicity, Social responsibility, Breast International Group, Research, AMF, BIG, Patient, COVID-19, Tamoxifen, SAN, Breast cancer, Partnership, SERD, Â, Safety, Treatment, NASDAQ, EORTC, AFT, Science, European Organization for Quality, Form 20-F, Annual report, Progression-free survival, Medicine, SNY, EMA, IDMC, Pharmaceutical industry, Medical imaging, Sanofi, Cancer

Sanofi is discontinuing the global clinical development program of amcenestrant, an investigational oral selective estrogen receptor degrader (SERD).

Key Points: 
  • Sanofi is discontinuing the global clinical development program of amcenestrant, an investigational oral selective estrogen receptor degrader (SERD).
  • Our sincere gratitude goes to the patients, families and healthcare professionals involved in the amcenestrant clinical development program.
  • Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
    This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended.
  • Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Sanofi provides update on Phase 2 study evaluating amcenestrant in ER+/HER2- advanced or metastatic breast cancer

Retrieved on: 
Monday, March 14, 2022
NASDAQ, Safety, Form 20-F, Annual report, Private Securities Litigation Reform Act, Partnership, Research, Survival, FDA, AMF, EMA, SNY, SERD, Breast International Group, Intellectual property, AFT, BIG, Science, MBC, PFS, Patient, Breast cancer, Treatment, EORTC, Progression-free survival, European Organization for Quality, Social responsibility, Population, COVID-19, SEC, Medicine, Forward-looking statement, SAN, ER, Birth control, Pharmaceutical industry, Sanofi, Cancer

No new safety signals were identified and the safety profile of amcenestrant in AMEERA-3 was consistent with earlier studies.

Key Points: 
  • No new safety signals were identified and the safety profile of amcenestrant in AMEERA-3 was consistent with earlier studies.
  • This Phase 2 trial evaluated amcenestrant as a monotherapy in a patient population with advanced disease where limited treatment options remain.
  • Sanofi will continue to assess data from the AMEERA-3 trial and work with investigators on the publication of the full results.
  • Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer

Retrieved on: 
Saturday, March 12, 2022
MSD, Association for Molecular Pathology v. Myriad Genetics, Inc., Risk, Partnership, Guideline, Cyprus Securities and Exchange Commission, Regulation of tobacco by the U.S. Food and Drug Administration, AstraZeneca, Health, Precision medicine, Private Securities Litigation Reform Act, Olympia, Classification, HIV disease progression rates, Breast cancer, HER2, Biomarker, Fast Company, FDA, Olaparib, Sumathi Best Television Current Reporting Award, National Cancer Institute, DNA, Merck, Ovarian cancer, GLOBE, Patient, Neoplasm, BRCA1, NASDAQ, Myriad Genetics, SALT, PARP, BRCA2, Breast International Group, New Frontiers Science Park, MYGN, Security (finance), Genetics, Genomics, Merck & Co., Genetic testing, Technology, State, BRCA, COVID-19, Food, Diagnosis, Pharmaceutical industry, Medical imaging, Myriad

This most recent regulatory approval confirms the benefits of using biomarkers to help guide care for patients with breast cancer, said Nicole Lambert, chief operating officer, Myriad Genetics.

Key Points: 
  • This most recent regulatory approval confirms the benefits of using biomarkers to help guide care for patients with breast cancer, said Nicole Lambert, chief operating officer, Myriad Genetics.
  • BRACAnalysis CDx is intended to detect and interpret germline BRCA1 and BRCA2 variants.
  • The test identifies deleterious or suspected deleterious germline BRCA variants in patients with HER2 negative high-risk early breast cancer.
  • BRACAnalysis is a companion diagnostic test that classifies a patients clinically significant variants (DNA sequence variations) in the germline BRCA1 and BRCA2 genes.